close

Agreements

Date: 2011-02-03

Type of information: Development agreement

Compound: purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates

Company: Novasep (France) instrAction (Germany)

Therapeutic area: Cancer - Oncology

Type agreement:

Development
Manufacturing
Production

Action mechanism:

Disease:

Details:

Novasep and instrAction have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds. This extended collaboration enables Novasep to develop and operate or supply optimized large-scale chromatography processes for cost-effective purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates. The two companies announced a strategic alliance covering non-chiral chromatography in July 2010. The extended relationship means Novasep adds enhanced taxane anti-cancer compound capabilities to its extensive range of manufacturing solutions for life science industries. Novasep customers will benefit from the collaboration as they will be able to access a cost-effective one-step purification solution for their taxane-based APIs. A large number of clinical trials involve paclitaxel and docetaxel, two of the leading anti-cancer APIs marketed today, and approved for the treatment of breast, ovarian, prostate, non small cell lung cancers, etc., and also new taxanes, taxane conjugates or combinations between taxanes and other APIs. Novasep develops and manufactures its customers’ taxane-based APIs and advanced intermediates at its FDA inspected and SafeBridge certified Le Mans site in France, specialized in highly potent API (HPAPI) synthesis and purification.

Financial terms:

Latest news:

Is general: Yes